Researchers have conducted an analysis of nationwide surveillance data from Israel demonstrating the real-world effectiveness of Pfizer-BioNTech’s BNT162b2 vaccine at protecting against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).